Profil
Dr Tania Papkovskaia is Senior Associate at Fountain Healthcare Partners.
Tania qualified with a BSc in Biochemistry from University College Dublin in 2009 and earned a PhD in Clinical Neuroscience from University College London, sponsored by Eisai Limited in collaboration with the Welcome Trust Consortium and the Institute of Neurology.
Her research was focused on Leucine Rich Repeat Kinase 2 in Parkinson’s Disease.
In addition, she conducted postdoctoral research at the department of Oncology, University of Cambridge, investigating the role of cyclin depended kinase inhibitors in neuroblastoma.
In 2014, Tania joined the Healthcare team at the Gerson Lehrman Group, providing diligence support to global healthcare investors, coordinating business development efforts and product campaigns across pharmaceutical, biotechnology and medical device segments.
In 2017, she took over the European Healthcare team, a $4.5 million division, with responsibility spanning revenue, commercial strategy, operational performance, training and development.
Postes actifs de Tania Papkovskaia
| Sociétés | Poste | Début |
|---|---|---|
Fountain Healthcare Partners Ltd.
Fountain Healthcare Partners Ltd. Investment ManagersFinance Fountain invests in life sciences companies located in Europe and the United States. The firm targets companies operating in the fields of specialty pharma, biopharmaceuticals, medical devices and diagnostics. The firm provides equity financing for seed to public offering capital requirements with an investment size of EUR 10- 15 million. The firm leads or co-leads an investment syndicate. | Analyste en capital-investissement | 01/01/2019 |
Formation de Tania Papkovskaia
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Fountain Healthcare Partners Ltd.
Fountain Healthcare Partners Ltd. Investment ManagersFinance Fountain invests in life sciences companies located in Europe and the United States. The firm targets companies operating in the fields of specialty pharma, biopharmaceuticals, medical devices and diagnostics. The firm provides equity financing for seed to public offering capital requirements with an investment size of EUR 10- 15 million. The firm leads or co-leads an investment syndicate. | Finance |
University College Dublin
University College Dublin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















